Roman Butler Fullerton & Co. Boosts Holdings in Danaher Co. (NYSE:DHR)

Roman Butler Fullerton & Co. increased its holdings in Danaher Co. (NYSE:DHR) by 5.3% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,314 shares of the conglomerate’s stock after purchasing an additional 66 shares during the period. Roman Butler Fullerton & Co.’s holdings in Danaher were worth $318,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. boosted its stake in shares of Danaher by 7.4% during the first quarter. Vanguard Group Inc. now owns 60,107,030 shares of the conglomerate’s stock valued at $15,009,928,000 after purchasing an additional 4,163,657 shares during the period. Wellington Management Group LLP raised its holdings in shares of Danaher by 12.0% during the fourth quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock valued at $6,460,966,000 after acquiring an additional 2,998,161 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in Danaher by 10.7% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after purchasing an additional 1,619,586 shares in the last quarter. Capital International Investors raised its stake in Danaher by 9.1% in the fourth quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after buying an additional 1,334,781 shares in the last quarter. Finally, Norges Bank purchased a new stake in Danaher in the fourth quarter worth about $1,752,382,000. Institutional investors own 79.05% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on DHR. Evercore ISI decreased their target price on Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a research report on Tuesday, July 2nd. Stifel Nicolaus boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a report on Wednesday, July 24th. Royal Bank of Canada increased their price target on shares of Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 24th. Citigroup boosted their price objective on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research note on Wednesday, April 24th. Finally, The Goldman Sachs Group raised their target price on shares of Danaher from $225.00 to $250.00 and gave the company a “neutral” rating in a research note on Wednesday, July 24th. Six research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $276.88.

Insider Buying and Selling at Danaher

In related news, CEO Rainer Blair sold 9,005 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were sold at an average price of $265.00, for a total value of $2,386,325.00. Following the transaction, the chief executive officer now owns 106,990 shares of the company’s stock, valued at $28,352,350. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the transaction, the chief financial officer now directly owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Rainer Blair sold 9,005 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the sale, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The disclosure for this sale can be found here. Insiders sold a total of 47,712 shares of company stock worth $13,173,269 in the last three months. 11.10% of the stock is currently owned by company insiders.

Danaher Stock Performance

Shares of NYSE DHR traded up $1.51 during trading on Tuesday, reaching $268.71. 1,823,557 shares of the company traded hands, compared to its average volume of 2,887,203. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The firm has a 50 day simple moving average of $257.42 and a 200-day simple moving average of $252.73. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The stock has a market capitalization of $199.03 billion, a PE ratio of 45.49, a P/E/G ratio of 4.62 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The firm’s quarterly revenue was down 2.9% on a year-over-year basis. During the same quarter last year, the company posted $2.05 earnings per share. Equities research analysts anticipate that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.